Notice NOT-CA-21-082 from the NIH Guide for Grants and Contracts

Competitive: Hyper Recruitment Solutions (HRS): Hyper Recruitment Solutions are excited to announce their partnership with a novel RNA Therapeutics business in the Cambridge area. We are exclusively supporting the recruitment -... Cambridge

Notice NOT-HD-21-032 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-023 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-029 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-071 from the NIH Guide for Grants and Contracts

Competitive Salary: F. Hoffmann-La Roche AG: Roche Postdoctoral Fellowship (RPF) in Genomic Medicine and Synthetic Biology (as of September 2021, 2 years) The RPF Programme has the ambition to b Switzerland (CH)

£38,200 - £41,802 per annum, depending on skills & exp (+£4k market supplement, reviewed annually): Royal Botanic Gardens, Kew : We are seeking to recruit a Lead Developer, with expertise in bioinformatics, to lead RBG Kew’s contribution to the AGENT... Kew, London (Greater)

Not specified: Hyper Recruitment Solutions (HRS): We are currently looking for a Product Scientist to join a leading medical company based in the Cambridgeshire area. As the Product Scientist you will... Cambridgeshire

Funding Opportunity RFA-HL-22-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (see RFA-HL-22-011).

New study highlights the challenges of reporting academic abuse—and the need for more oversight

The USGS EESC-PCG requires services to support collection, analysis and interpretation of conservation genetic and genomic data, and to summarize findings in a…
From Akima, LLC - Mon, 24 May 2021 20:59:05 GMT - View all Kearneysville, WV jobs

Competitive Salary: F. Hoffmann-La Roche AG: We seek a highly motivated Scientist within the Oncology Biomarker Development (OBD) Data Science Digital Pathology Group, to drive digital pathology Switzerland (CH)

Funding Opportunity RFA-DA-22-030 from the NIH Guide for Grants and Contracts. This FOA invites investigations into neurocognitive mechanisms by which socioeconomic inequality impacts various points in the substance use trajectory.

Funding Opportunity RFA-DA-22-024 from the NIH Guide for Grants and Contracts. This FOA invites investigations into neurocognitive mechanisms by which socioeconomic inequality impacts various points in the substance use trajectory.

Funding Opportunity RFA-DA-22-007 from the NIH Guide for Grants and Contracts. This FOA invites investigations into neurocognitive mechanisms by which socioeconomic inequality impacts various points in the substance use trajectory.

Funding Opportunity RFA-DA-22-005 from the NIH Guide for Grants and Contracts. This FOA invites investigations into neurocognitive mechanisms by which socioeconomic inequality impacts various points in the substance use trajectory.

Funding Opportunity RFA-DA-22-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement [FOA] is to encourage basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.

Funding Opportunity PAR-21-230 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. The main focus of research training covered in the application must be relevant to the interests of at least one of the participating NIH ICs as stated by each in this FOA. Other NCD topics may be included as secondary and complementary focus areas. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary study to an existing trial; or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Funding Opportunity RFA-MH-21-226 from the NIH Guide for Grants and Contracts. Companion to R01 (RFA-MH-21-225). The shock and kill strategy is one of the commonly used approaches for targeting latent reservoirs in hopes to cure HIV-1. It is based on the concept of purposely inducing reactivation of latent reservoirs in ART (antiretroviral therapy)-treated individuals by using stimulatory agents. However, it has become increasingly evident that attempts at elimination of HIV-1 reservoirs through latency reactivating agents (LRA) -mediated reactivation alone may not be sufficient. Novel strategies such as immunotherapy and gene excision therapies to optimize the recognition and elimination of reservoir cells such are being conceptualized and researched. Immunotherapy strategies like therapeutic vaccines to enhance HIV-1-specific CTL (cytotoxic T-cell) response, Chimeric Antigen Receptor T-cells (CAR-T cells) therapies, broadly neutralizing antibodies, dual-affinity retargeting antibodies that not only bind to HIV-1 viral envelope antigen but also activate the CTL response, and immune modulators, such as anti-PD1 (programmed cell death protein-1) or anti-CTL4 antibodies, to correct the immune exhaustion noticed in ART-treated individuals are being developed. In addition to immunotherapy strategies, Recombinant TALEN or CRISPR/Cas9 gene editing molecules delivered to latently infected cells designed to induce cleavage at highly conserved regions of the integrated HIV provirus genome are being researched. However, majority of immunotherapy-based and gene editing based HIV eradication strategies are focused on the periphery. The brain presents a unique challenge where access is difficult and innovative strategies are needed to overcome the blood brain barrier. It is also important to understand the potential CNS toxicity of immunotherapy-based and gene-editing based approaches currently being tested in clinical trials.